BioSpace News Archive

The tissue engineering market was valued at US$ 9,529.21 million in 2019 and is expected to grow at a CAGR of 13.5% from 2020 to 2027 to reach US$ 25,586.55 million by 2027.

Psomagen, Inc., a CLIA-certified genetic analysis service provider, is adapting to the public’s changing COVID-19 testing needs by expanding its SARS-CoV-2 diagnostic services.

PulsePoint, a technology company revolutionizing health decision-making in real-time, today announced the next generation launch of its digital media buying platform, Life by PulsePoint™.

The global Genomic Biomarkers market accounted for USD 5.5 billion in 2020 and is expected to reach USD 19.7 billion by 2028, growing at a CAGR of around 17.5% between 2021 and 2028.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that key data regarding standard risk patients undergoing treatment for atherosclerotic carotid disease, including patients undergoing carotid endarterectomy (CEA) and transcarotid artery revascularization (TCAR), will be presented at the upcoming Society for Vascular Surgery 2021 Vascular Annual Meeting (VAM),

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive top-line results from its confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for opioid overdose.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with at least one G542X allele.

LGC Maine Standards¹ announces the release of VALIDATE® UC1, VALIDATE® UC4, and VALIDATE® UC5 to meet the linearity and calibration verification needs of clinical laboratories running the Abbott ARCHITECT or Abbott ALINITY platform.

Analytical standards market drivers include stringent regulatory norms for quality control in pharmaceutical and food and beverages industries and increasing public-private investments for R&D.